| Company | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| DEXCOM INC | EVP Chief Commercial Officer | Common Stock | 66,641 | $8,957,263 | $134.41 | 12 Mar 2024 | Direct |
| Celldex Therapeutics, Inc. | SVP & Chief Commercial Officer | ISO (right to buy) | 100,000 | 10 Nov 2025 | Direct | ||
| Altimmune, Inc. | Director | Stock Options (option to buy) | 48,800 | 25 Sep 2025 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Role | Filing Time |
|---|---|---|---|---|---|---|---|
| CLDX | Celldex Therapeutics, Inc. | 10 Nov 2025 | 1 | $0 | 4 | SVP & Chief Commercial Officer | 12 Nov 2025, 16:12 |
| CLDX | Celldex Therapeutics, Inc. | 10 Nov 2025 | 0 | $0 | 3 | SVP & Chief Commercial Officer | 12 Nov 2025, 16:05 |
| ALT | Altimmune, Inc. | 25 Sep 2025 | 1 | $0 | 4 | Director | 29 Sep 2025, 16:19 |
| ALT | Altimmune, Inc. | 24 Feb 2025 | 1 | $0 | 4 | Director | 26 Feb 2025, 18:47 |
| ALT | Altimmune, Inc. | 24 Feb 2025 | 0 | $0 | 3 | Director | 26 Feb 2025, 18:46 |
| DXCM | DEXCOM INC | 12 Mar 2024 | 1 | -$640,333 | 4 | EVP Chief Commercial Officer | 14 Mar 2024, 17:39 |
| DXCM | DEXCOM INC | 08 Mar 2024 | 1 | $0 | 4 | EVP Chief Commercial Officer | 11 Mar 2024, 18:31 |
| DXCM | DEXCOM INC | 08 Mar 2023 | 1 | +$45.35 | 4 | EVP Chief Commercial Officer | 10 Mar 2023, 15:00 |
| DXCM | DEXCOM INC | 09 Jan 2023 | 0 | $0 | 3 | EVP Chief Commercial Officer | 09 Jan 2023, 15:35 |